Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS6807
- Development stage
- Unknown
- Lead developer
- Suncadia Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HRS6807 is a selective small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene), currently under development by Fujian Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Pharmaceuticals. Nav1.8 is a key mediator of nociceptive signaling in peripheral sensory neurons, and its selective inhibition is a promising strategy for treating pain without the side effects associated with non-selective sodium channel blockers or opioids. HRS6807 is being investigated for the management of various pain conditions, including postoperative pain, and has progressed into Phase 2 clinical trials in China.
02
Targets
SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on HRS6807.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS6807.